Precision BioSciences (DTIL) Stock Price, News & Analysis

Company Overview

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area. The company completed a business combination with a special purpose acquisition company (SPAC) in 2021 and began trading on the Nasdaq under the ticker DTIL. Over its history, Precision BioSciences has focused on optimizing ARCUS for high specificity, efficiency and manufacturability, laying the groundwork for scalable gene editing solutions.

Precision BioSciences is led by President and Chief Executive Officer Matt Kane, who has steered the company’s scientific and strategic initiatives since joining in 2014. Under his leadership, the company has established collaborations with academic institutions and biopharmaceutical partners to advance preclinical studies and clinical trials. With a focus on innovation and translational research, Precision BioSciences aims to bring next‐generation gene therapies from discovery through to regulatory approval and commercialization.

Key Stats

• Today's Range: $7.21 to $7.60
• 50-Day Range: $3.99 to $7.91
• 52-Week Range: $3.53 to $8.82
• Volume: 152,208 shs
• Average Volume: 218,740 shs
• Market Capitalization: $192.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.33
• Consensus Rating: Moderate Buy

Precision BioSciences Stock Analysis - MarketRank™

Precision BioSciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 698th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Precision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Precision BioSciences has a consensus price target of $36.33, representing about 385.7% upside from its current price of $7.48.

Amount of Analyst Coverage

Precision BioSciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Precision BioSciences are expected to decrease in the coming year, from ($1.17) to ($1.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Precision BioSciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precision BioSciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precision BioSciences has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.06% of the float of Precision BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Precision BioSciences has a short interest ratio ("days to cover") of 4.63.

Change versus previous month

Short interest in Precision BioSciences has recently increased by 6.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precision BioSciences does not currently pay a dividend.

Dividend Growth

Precision BioSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: -0.91

News Sentiment

Precision BioSciences has a news sentiment score of -0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Precision BioSciences this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for DTIL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $129,151.00 in company stock.

Percentage Held by Insiders

2.70% of the stock of Precision BioSciences is held by insiders.

Percentage Held by Institutions

37.99% of the stock of Precision BioSciences is held by institutions.

DTIL Stock Analysis - Frequently Asked Questions

How have DTIL shares performed this year?

Precision BioSciences' stock was trading at $4.16 at the start of the year. Since then, DTIL shares have increased by 79.8% and is now trading at $7.48.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) released its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.10. The business had revenue of $10.84 million for the quarter, compared to analyst estimates of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative trailing twelve-month return on equity of 98.12%.

When did Precision BioSciences' stock split?

Shares of Precision BioSciences reverse split on the morning of Wednesday, February 14th 2024.The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Precision BioSciences IPO?

Precision BioSciences (DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Enovix (ENVX), Nokia (NOK) and Ginkgo Bioworks (DNA).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DTIL
• CIK: 1357874
• Web: www.precisionbiosciences.com
• Phone: (919) 314-5512
• Fax: N/A
• Employees: 200
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Precision BioSciences: $36.33
• High Price Target: $60.00
• Low Price Target: $19.00
• Potential Upside/Downside: +385.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.72 million
• Net Margins: -96.73%
• Pretax Margin: -136.03%
• Return on Equity: -98.12%
• Return on Assets: -39.30%

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 13.32
• Quick Ratio: 13.32

Sales & Book Value

• Annual Sales: $34.26 million
• Price / Sales: 5.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.03 per share
• Price / Book: 1.86

Miscellaneous

• Outstanding Shares: 25,800,000
• Free Float: 25,106,000
• Market Cap: $192.98 million
• Optionable: No Data
• Beta: 1.31